Open Access

Rocío Llamas-Ramos

Research

Covid-19 impact on Spanish population. Symptom's prevalence and protocols followed

Fátima Pérez-Robledo, Beatriz María Bermejo-Gil, Rocío Llamas-Ramos*, Juan Luis Sánchez-González and Inés Llamas-Ramos

Department of Nursing and Physiotherapy, Faculty of Nursing and Physiotherapy, Universidad de Salamanca, Salamanca, Spain.

*Corresponding Author: Rocío Llamas-Ramos, Department of Nursing and Physiotherapy, Faculty of Nursing and Physiotherapy, Universidad de Salamanca, Salamanca, Spain.

Received date: March 12, 2022; Accepted date: April 25, 2022; Published date: June 04, 2022

Citation: Fátima Pérez-Robledo, Beatriz María Bermejo-Gil, Rocío Llamas-Ramos, Juan Luis Sánchez-González and Inés Llamas-Ramos. (2022). Covid-19 impact on Spanish population. Symptom's prevalence and protocols followed. *Journal of Clinical Case Reports and Studies* 3(5); DOI: 10.31579/2690-8808/114

Copyright: © 2022 Rocío Llamas-Ramos, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: The SARS-CoV-2 generates a global health emergency due to the high incidence of diagnosed cases of Covid-19. Spain has been one the most affected countries. The information about the evolution and complications of this new and unpredictable disease is low. Epidemiological studies made necessary to establish the most appropriate treatments.

Objective: To establish the Spanish population characteristics in relation to Covid-19, symptoms, diagnosis and quarantine mean days.

Design: Epidemiological study.

Methods: The questionnaire was designed with Covid-19 questions and demographic data of the sample. It had several sections, as an informative sheet and informed consent, participant's demographic data, Covid-19 diagnosis, hospital admissions and quarantine among others.

Results: 1500 answers have been collected via WhatsApp, social networks and email among all the Spanish population. The most affected age was people between 40-65-years old (53,9%), being more prevalent in women (67.8%); the blood group more prevalent was A+(31.5%) and the most frequent symptoms were severe tiredness (68.2%), myalgia (65%) and headaches (64.6%).

Conclusion: The study provides relevant data about the general Spanish population on the third wave in relation to Covid-19 patients. The online survey has been the safest method for collecting information from the general population. More epidemiological studies on the general are needed to collect information on Covid-19 symptoms.

Key words: covid-19, prevalence, symptom, survey, spanish population

Introduction

The current outbreak of SARS-CoV-2 in the Wuhan province of China has spread to almost all the countries of the world, generating a global health emergency due to the high incidence of diagnosed cases of Covid-19.

Currently, a total of 83 million people has been infected by the virus. The incidence increases by 4 million cases, with 76,000 deaths each week [1]. Spain is one of the most affected countries. During the first wave of the pandemic, more than 200,000 cases of infected people were recorded, of which 12% died because of the disease [2]. Nowadays, more than 2 million cases of infected people have been counted [3].

On December 27. 2020, Spain presents a total of 12.172 people admitted for Covid-19, filling 10.04% of hospital beds. Likewise, 2.022 people are admitted to the Intensive Care Units (ICU) filling 21.14% of the beds in these units [4]. Regarding mortality, it is estimated that around 48.926 have died [5]. These data guide us that we would be at the door of a third wave.

The most common symptoms of the disease are fever, dry cough and fatigue. Other less common symptoms are muscle aches and pains, sore throat, conjunctivitis, loss of sense and smell, and skin rashes or loss of color on the fingers, as well as gastrointestinal disorders and asymptomatic infections [6-9]. Regarding the incubation period, some studies estimate that it oscillates around 3-5 days [10].

Considering diagnosis, the main method is the collection of samples from the upper respiratory tract using nasopharyngeal and oropharyngeal swabs [8].

To determine the consequences of the pandemic, online surveys have become a promising method of synthesizing the situation of the population [11, 12]. There are more and more studies that use this type of survey to assess how the population is perceiving this Covid-19 outbreak or to analyze the prevalence and impact due to the disease [12-14].

The aim of this study has been to apply a rapid online survey to determine the Spanish situation on the third wave of the pandemic.

Objective

Epidemiological study to establish the Spanish population's characteristics in relation to Covid-19, symptoms, diagnosis, and quarantine mean days to determine the most appropriate action protocol.

Methods

The questionnaire included Covid-19 questions about a representative population sample.

The questionnaire was designed through "Google Forms". Prior to its completion, the participants read an information sheet (first section), where the objectives were described, and the questionnaire characteristics were reported.

The questionnaire consisted of 5 sections: "participant's information", "demographic data", "Covid-19", "Covid-19 positive" and "acknowledgement". All sections had to be completed. Finally, an acknowledgement section for the collaboration in the study was presented. The sections are explained below.

First section: information for participants. Study design description, objective, questionnaire brief description, benefits and risks of filling it, confidentiality and research team information. At the end of the section, participants must check the box for informed consent acceptance to confirm the information reading and understanding, as well as their voluntary participation before accessing the questionnaire.

Second section: demographic data, birth date (day, month, year), gender (woman or man), blood group (A+, A-, B+, B-, AB+, AB-, 0+, 0-, don't know); previous diagnosed illnesses were asked with the following options: diabetes, arterial hypertension, heart disease, asthma, chronic obstructive pulmonary disease, allergy, vascular disorders, stroke, cancer, transplantation, hepatitis and psychiatric illness; region and province residence (19 and 52 options respectively), live area ("rural" or "urban") and people who make up your family unit / coexist with you.

Third section: Covid-19. This section consisted of a single question: "Have you suffered from Covid-19? With 3 possible answers: "yes", "no" and "I don't know".

Fourth section: Covid-19 positive. In this section 9 questions have been included. "What month did you suffer from the disease in?" was asked and the 12 possible options corresponding to the 12-year months. Diagnosis was the next question. In this case, the question asked was "Indicate how were you diagnosed" with 4 answers' options "PCR (swab in nose)", "Antigen test with capillary blood sampling (finger prick)", "Antigen test with nasopharyngeal" and "Serology (analytical)". The answer selection was dichotomous "yes" or "no". The following question was: "Was the test repeated?" and the possible answers were "yes" or "no". The next one: "How many days elapsed between the tests?" with a short text answer as an option. Symptoms conformed to the following section: "Have you suffered any of these symptoms?" A list of 17 symptoms was described and the answer had to be "yes" or "no" for each symptom. The symptoms were: "fever", "chills", "cough", "sore throat",

"headache", "anosmia (loss of smell)", "ageusia (loss of taste)", "myalgia (muscle aches)", "severe tiredness", "dyspnea (feeling short of breath)", "chest pain or pressure", "nausea, vomiting, diarrhea", "cyanosis (bluish lip color)", "confusion or drowsiness", "skin rashes", "other symptoms" and "asymptomatic". Information was also collected on "How many days did the symptoms last?". The next question was: "Did you have to be hospital admitted?" with 2 possible answers "yes" or "no". Finally, quarantine information was requested: "How many days did you have to quarantine?". The last question was: "Were you able to remain separated from others in your home during the quarantine?" In this case the options were "yes", "no" or "not applicable".

Fifth section: Acknowledgment. An acknowledgment section was included after conducting the survey for the collaboration offered. Participants who answered "No" or "I don't know" in the third section were directly managed to this one.

All questionnaire questions were mandatory except those mentioned above about the time elapsed between the 2 tests in the event of not having performed a second diagnostic test and the one related to the symptom's duration, since the participants may not have had any symptoms. Both in section 4.

A first draft was made, and external collaborators were requested for opinion to carry out a pilot test. After this test, all those erroneous or confusing aspects were collected and corrected in the next questionnaire version. A second test was performed to ensure that the questionnaire collected those variables that were to be measured. Sections were well understood and there were no errors in questions formulation.

An informative sheet and the questionnaire were distributed via WhatsApp, social networks and email. Present a mobile device to complete the questionnaire and have full mental faculties to be able to fill it out were the inclusion criteria. No exclusion criteria were established in relation to age, level of education or training or geographical location. The questionnaire was registered in clinical trials with the registry number: NCT04659473.

The sample recruitment was carried out in December 2020. If any participant had doubts, they were able to contact the research team through the email located in the information sheet in the first section of the questionnaire.

IBM-SPSS Statistics (version 26) was employed for Statistical analysis. A descriptive analysis was performed, using the mean and standard deviation as descriptors for quantitative data and counts and percentages in the case of qualitative variables. A 95% safety level was considered. Cross tables were also made to see the relationship between some variables.

Results

A total of 1500 participants completed the online survey of our study, 67.8% of them were women and the mean age of the sample was 41.97 ± 12.8 years-. 32% of the participants were from Castilla y León, with 21.7% of the sample from Salamanca. 21% of the participants belonged to the Community of Madrid, and the rest were distributed among the other regions of our country (Figure 1). 81.7% of the sample lived in urban areas, with an average number of cohabitants in each family unit of 2.91 ± 1.16 people.

Regarding their clinical history, a low prevalence of the evaluated diseases was observed, being more frequent the presence of allergies (26.4%), asthma (9.2%) and arterial hypertension (7.2%). The rest of the diseases were not representative. The most frequent blood groups were A+ and 0+, accounting for 59.2% of the sample between them. The rest was distributed among the rest of the groups or those participants who did not know it (Table 1).

J, Clinical Case Reports and Studies

14.9% of the participants of our sample suffered from Covid-19 at some moment, March, October, and November were the most prevalent months.

The diagnosis tests more used were PCR and serology. More than half of the Covid-19 patients had the test repeated to check the persistence of the virus with a mean time between tests of 19.48 ± 27.46 days.

The most frequent symptoms were intense tiredness, myalgia, headache, cough, fever and anosmia, which appeared in more than half of the people who suffered from the disease. The rest of the symptoms did not appear in so many cases, skin conditions was the least present (1.8%). Only 7.2% of our sample turned out to be asymptomatic. These symptoms remained in the patients for a mean time of 52.48 days. The symptom's severity led to admission to 9.4% of the participants with Covid-19.

Most Covid-19 patients had to quarantine for more than 10 days, and in many cases, they had no problem staying separated from other people at home (Table 2).

Both men and women had a similar proportion of infected people around 15%. The age group with the highest proportion of positive cases were

those between 40 and 65 years old, followed by those under 40 years of age and lastly, the elderly. The area of residence did not influence the number of infections, both of which presented a percentage of around 15%. No differences were observed in terms of the number of partners in the home.

Women had more frequent cough, fever and myalgia, while men had headache, severe fatigue and myalgia. People under 65 years of age presented to a greater extent intense fatigue, myalgia, headache and cough, while the elderly were affected mainly by fever and myalgia (7%).

In relation to the blood group, groups B- and 0- were the ones with the highest proportion of people with the disease (26.9% and 19.4%). People with transplantation, diabetes, psychiatric illness, chronic obstructive pulmonary disease and arterial hypertension were more likely to contract the virus (>20%) (Table 3).

Finally, considering the symptoms distribution in relation to the blood groups, the people with groups A had myalgia (8.4% and 11.2%) to a greater extent (6.7% and 9.2%), those with group 0 had intense fatigue (12% and 13.9%), and in the rest of the groups there was a greater distribution of symptoms without any predominant (Table 4).

Variable		N (%)				
COVID-19	Yes	223 (14.9%)				
	No / Don't know	1277 (85.1%)				
	March	114 (51.3%)				
	April	22 (9.9%)				
Month	May	3 (1.3%)				
	June	1 (0.4%)				
	July	1 (0.4%)				
	August	8 (3.6%)				
	September	12 (5.4%)				
	October	28 (12.6%)				
	November	28 (12.6%)				
	December	6 (2.7%)				
	PCR	129 (57.8%)				
Diagnostic Method	Antigen (capillary blood)	26 (11.7%)				
	Antigen (nasopharyngeal)	32 (14.3%)				
	Serology	96 (43%)				
Retest	Yes	125 (56.1%)				
	No	98 (43.9%)				
Time between test (days)		19.48 ± 27.46				

 Table 1. Descriptive data of total sample

	Fewer	126 (56.5%)
	Chills	105 (47.1%)
	Cough	133 (59.6%)
	Sore throat	91 (40.8%)
	Headache	144 (64.6%)
	Anosmia	114 (51.1%)
	Ageusia	100 (44.8%)
Symptoms	Myalgia	145 (65%)
	Severe tiredness	152 (68.2%)
	Dyspnea	90 (40.4%)
	Chest pain	82 (36.8%)
	Nausea, vomiting, diarrhea	97 (43.5%)
	Cyanosis	4 (1.8%)

Confusion or drowsiness	66 (29.6%)
Skin rashes	45 (20.2%)
Other symptoms	60 (26.9%)
Asymptomatic	16 (7.2%)
	52.48 ± 82.28
Yes	21 (9.4%)
No	202 (90.6%)
10 days	51 (22.9%)
10 - 20 days	69 (30.9%)
20 days	20 (9%)
> 20 days	83 (37.2%)
-	Other symptoms Asymptomatic Yes No 10 days 10 - 20 days 20 days

^a Mean (Standard deviation)

Table 2. Covid-19 characteristics

	N (%)
	15%
	14.5%
	11.7%
	17.8%
	7%
	15.6%
Urban	14.7%
1	17.5%
2	14.7%
3	14.6%
4	14.7%
5	11.8%
6	9.1%
A+	13.4%
A-	11.2%
B+	17.6%
B-	26.9%
AB+	16.4%
AB-	14.3%
0+	15.7%
0-	19.4%
Don't Know	12.4%
	26.7%
	20.4%
	14%
	16.7%
	22.2%
	13.8%
	13.8%
	2 3 4 5 6 A+ A- B+ B- AB+ AB- 0+

Psychiatric illness	23.9%
Cancer	17.9%
Transplantation	33.3%
Hepatitis	12.5%

Table 3. Descriptive data of Covid+ sample

Vari	able	Fe	С	Со	Sor	He	An	Ag	M	Seve	Dy	Ch	Na	Су	Со	Sk	Other	Asymptom
		ver	h	ug	е	ad	os	eu	yal	re	sp	est	us	an	nfu	in	sympt	atic
			il	h	thro	ac	mi	sia	gia	tired	ne	pai	ea	osi	sio	ras	om	
			ls		at	he	a			ness	a	п		\$	п	h		
Gend	Wo	8.1	7.	8.7	6.6	10.	8.3	7.3	10.	11%	6.4	6%	7.1	0.3	4.6	3.1	4.3%	0.9%
er	men	%	2	%	%	2	%	%	1		%		%	%	%	%		
			%			%			%									
	Men	9%	6.	9.3	4.8	8.1	5.9	5.2	8.6	8.1%	5	4.3	5	0.2	3.8	2.7	3.4%	1.6%
			6	%	%	%	%	%	%		%	%	%	%	%	%		
			%															
	<40	4.9	3.	6.2	4.9	6.3	6%	5.1	6.2	6.6%	3.2	3.9	3.7	0.2	1.8	2	1.8%	0.9%
	year	%	7	%	%	%		%	%		%	%	%	%	%	%		
Age	s		%															
grou	40-	11.	9.	11.	7.1	12.	9.3	8.2	12.	13.2	8.5	7.1	9	0.4	6.6	3.8	5.8%	1.2%
р	65	3%	8	3	%	6	%	%	6	%	%	%	%	%	%	%		
	year		%	%		%			%									
	s																	
	. (5	7%	4.	4.7	4.7	2.3	0	2.3	7	4.7%	0	0	0	0	22	2.3	2.3%	0
	>65	7%	4. 7	4.7 %	4.7 %	2.3 %	0	2.3 %	%	4.7%	0	0	0	0	2.3 %	2.3 %	2.3%	0
	year		%	%	%0	%		%	%						%0	%0		
	s																	
	A+	6.7	5.	6.5	4.1	7.5	5.3	4.7	8.4	8.4%	5.5	4.9	5.3	0	3.1	1.8	3.1%	1.4%
		%	3	%	%	%	%	%	%		%	%	%		%	%		
			%															
	A-	9.2	6.	8.2	5.1	8.2	8.2	5.1	11.	9.2%	5.1	3.1	3.1	1	4.1	5.1	6.1%	0
		%	1	%	%	%	%	%	2		%	%	%	%	%	%		
Bloo			%						%									
d	B+	13.	9.	11	5.5	14.	8.8	7.7	8.8	13.2	11	6.6	12.	1.1	6.6	5.5	6.6%	1.1%
Grou		2%	9	%	%	3	%	%	%	%	%	%	1	%	%	%		
	D	15	%	10	15.4	%	10	10	15	11.5	15	11	%	0		77	2.90/	0
	B-	15.	1	19. 2	15.4 %	15. 4	19. 20/	19. 2	15.	11.5 %	15.	11.	11. 5	0	7.7	7.7 %	3.8%	0
		4%	9. 2	2 %	%	4 %	2%	2 %	4 %	%	4 %	5%	5 %		%	%		
			2 %	70		70		70	70		70		70					
	AB+	13.	6.	8.2	8.2	13.	9.8	8.2	13.	13.1	8.2	6.6	8.2	1.6	8.2	1.6	4.9%	0
		13. 1%	0. 6	8.2 %	8.2 %	15.	9.8 %	8.2 %	13.	13.1 %	8.2 &	%	8.2 %	1.0 %	8.2 %	1.0 %	4.270	0
		1/0	%	70	70	%	70	70	%	70	a	70	70	70	70	/0		
	AB-	0	1	0	14.3	14.	14.	14.	14.	14.3	14.	14.	14.	0	14.	14.	14.3%	0
	7.D-	0	4.	0	%	3	3%	3	3	%	3	3%	3	0	3%	3	14.370	0
					,0	%	070	%	%	,0	%	070	%		270	%		
1						/0		/0	/0		/0		/0			/0		

				3																
				%																
		0+	8.3	9.	9.7	7.6	11.	9%	7.9	11.	12%	6	6%	8.3	0.2	6.3	3.7	5.1%	1.9%	
			%	5	%	%	6		%	6		%		%	%	%	%			
Table				%			%			%										4.
		0-	10.	8.	13.	8.3	10.	9.3	8.3	11.	13.9	7.4	6.5	5.6	0	3.7	1.9	3.7%	0	
			2%	3	9	%	2	%	%	1	%	%	%	%		%	%			
				%	%		%			%										
	р	Do´t	7%	2.	8.6	4.8	6.5	5.9	5.9	5.4	5.9%	2.2	4.3	3.2	0	1.1	2.2	1.1%	0.5%	
		kn0		2	%	%	%	%	%	%		%	%	%		%	%			
		w		%																
							Tabl	e 4. Sı	mptor	ns in i	relation	to ger	ider. a	ige an	d			1	<u>. </u>	

 Cable 4. Symptoms in relation to gender, age and blood group

Figure



Figure 1. Positive cases proportion in Spain

Discussion

Through the survey responses, we have identified interesting factors that can contribute to the study of the population in this third wave of the pandemic.

First, our study highlights the use of online questionnaires can safely assess the general population, providing data on non-hospitalized patients and reaching larger sample numbers [15].

Our sample tried to have a representation of each region, although this representation was not balanced between all geographical areas. This makes it difficult to clarify precisely the behavior that the virus has had in the different regions. However, regarding the area of residence, although differences were found between the two, they were expected. The Spanish population has been in a rural-urban migration since the 1960s [16], which is observed in the population of our study.

Secondly, it should be noted that the incidence of Covid-19 data obtained

Auctores Publishing LLC – Volume 3(4)-114 www.auctoresonline.org ISSN: 2690-8808 in our study (15%) agrees with the data obtained by the Spanish Health Ministry, that estimate the prevalence at 9.9%. Regarding the incidence by autonomous communities, the Health Ministry study observes a marked geographical variability, coinciding with the data obtained in our study [17].

One of the findings that differ with the scientific literature is the presence of the same form of infections in the urban and rural population, unlike what was observed in previous stages [18]. It was shown a higher prevalence of the disease in the urban environments.

The diagnostic test most used to detect the virus was the PCR. This makes sense if we consider that it is the gold standard in detection of SARS-CoV-2 [19]. Some medical history predicted the possibility of contagion, such as chronic obstructive pulmonary disease or cardiovascular conditions, which had also previously been related to a worse prognosis [20,21].

Regarding the symptoms, and coinciding with other studies, the most frequent symptoms were intense fatigue, myalgia, headache, cough, fever and anosmia [22]. The mean duration of symptoms was 52.48 days, exceeding 9 months in some cases. These figures are much higher than that reported by different authors, who place the recovery time at approximately 10 days [22]. The prevalence of asymptomatic patients in our sample is much lower than that reported by other studies, which postulate that around 40% of cases may be asymptomatic; evidencing in a way the need for screening to identify these patients [23].

An ABO blood group to SARS-CoV-2 is hypothesized, different authors show an association of group A with a greater number of cases [24-25].

However, in our study, although there was representation of all groups, positive cases had a higher prevalence in subjects with group B and 0, although it is true that the subjects of group A shown more severe symptoms. These data can be explained, since studies on the association between AB0 blood groups and SARS-CoV-2 have been performed in hospital patients [26], showing higher mortality in group A patients [24]. It is possible that when our study was conducted in the general population, the data vary, and the frequency of contagion was shown in another sense by not analysing only those patients who had severe symptoms. Our study reviews the results of the frequency of symptoms, not their intensity, it could be that even with fewer symptoms, group A participants had a worse prognosis and a greater probability of ending up in hospital.

Regarding the isolation period, the study shows how the population correctly carried out the necessary period, being even higher, since it is known that the viral load of SARS-CoV-2 viral load appeared to peak in the first week of illness, whereas at days 10–14 not infective virus has been found [27].

One of the greatest strengths of our study is that it was based on the general population, analyzing the situation prior to the third wave in Spain, with a representative simple, collecting information on how they have experienced the situation to face the new waves.

The major limitation was the disparity of participation between communities because some communities had low participation.

Conclusions

This study provides relevant data about the general Spanish population before the third wave. The survey was well received and participated. In addition, it has been the safest method for collecting information from the general population.

Acknowledgements

To Dr. Miguel Marcos and all our participants for their collaboration and questionnaire diffusion.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

- 1. World Health Organization. COVID-19 (2021) Weekly Epidemiological Update.
- 2. Working group for the surveillance and control of COVID-19 in Spain. (2020) The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe

outcomes, as at 27 April 2020. Eurosurveillance [Internet]. 17 de diciembre de [citado 9 de enero de 2021];25(50).

- Centro de Coordinación de Alertas y Emergencias Sanitarias. (2021) Actualización nº 286. Enfermedad por el coronavirus (COVID-19). [Internet]. [cited Jan 9 2021].
- 4. Sanitarias C de C de A y E. Actualización nº 279. Enfermedad por el coronavirus (COVID-19). 28.12.2020. 2020:3.
- 5. Johns Hopkins University. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE).
- 6. Organización Mundial de la Salud (OMS). (2020) Preguntas y respuestas sobre la enfermedad por coronavirus (COVID-19).
- Chan JFW, Yuan S, Kok KH, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet.*;395(10223):514-523. doi:10.1016/S0140-6736(20)30154-30159
- Pascarella G, Strumia A, Piliego C, et al. (2020) COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 288(2):192-206. doi:10.1111/joim.13091
- Wu D, Wu T, Liu Q, Yang Z. (2020) The SARS-CoV-2 outbreak: What we know. *Int J Infect Dis.* 2020. 94:44-48. doi: 10.1016/j.ijid..03.004
- Guan WJ, Ni ZY, Hu Y, et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. China Medical Treatment Expert Group for Covid-19. *N Engl J Med.* 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032
- Geldsetzer P. (2020) Use of Rapid Online Surveys to Assess People's Perceptions During Infectious Disease Outbreaks: A Cross-sectional Survey on COVID-19. J Med Internet Res. 22(4):e18790. doi: 10.2196/18790.
- Wang P, Lu W, Ko N, et al. (2020) COVID-19-Related Information Sources and the Relationship With Confidence in People Coping with COVID-19: Facebook Survey Study in Taiwan. J Med Internet Res. 22(6):e20021. doi: 10.2196/20021.
- Zhong BL, Luo W, Li HM, et al. (2020) Knowledge, attitudes, and practices towards COVID-19 among chinese residents during the rapid rise period of the COVID-19 outbreak: A quick online cross-sectional survey. *Int J Biol Sci.* 16(10):1745-1752. doi:10.7150/ijbs.45221
- Estrich CG, Mikkelsen M, Morrissey R, et al. (2020) Estimating COVID-19 prevalence and infection control practices among US dentists. *The Journal of the American Dental Association*. 151(11):815-24. doi: 10.1016/j.adaj.2020.09.005.
- Oliver N, Barber X, Roomp K, Roomp K. (2020) Assessing the Impact of the COVID-19 Pandemic in Spain: Large-Scale, Online, Self-Reported Population Survey. J Med Internet Res. 10:22(9):e21319. doi: 10.2196/21319.
- Rivero-Jiménez B, Conde-Caballero D, Mariano-Juárez L. (2020) Health and Nutritional Beliefs and Practices among Rural Elderly Population: An Ethnographic Study in Western Spain. *Int J Environ Res Public Health.* 14;17(16):5923. doi: 10.3390/ijerph17165923.
- Ministerio de Sanidad. (2020) Estudio ENE-COVID: cuarta ronda estudio nacional de sero-epidemiología de la infección por SARS-CoV-2 en España. Instituto de Salud Carlos III. 15 December [Access: 17 January 2021].
- Paul R, Arif AA, Adeyemi O, Ghosh S, Han D. (2020) Progression of COVID-19 From Urban to Rural Areas in the United States: A Spatiotemporal Analysis of Prevalence Rates. *J Rural Health*. 36(4):591-601. doi: 10.1111/jrh.12486.
- Yüce M, Filiztekin E, Özkaya KG. (2021) COVID-19 diagnosis -A review of current methods. *Biosens Bioelectron*. 15;172:112752. doi: 10.1016/j.bios.2020.112752

- Zhao Q, Meng M, Kumar R, et al. (2020) The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. *J Med Virol.* 92(10):1915-1921. doi: 10.1002/jmv.25889
- Chen C, Chen C, Yan JT,et al. (2020) Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. Zhonghua Xin Xue Guan Bing Za Zhi. 24;48(7):567-571. doi: 10.3760/cma.j.cn112148-20200225-00123.
- Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol.* 277(8):2251-2261. doi: 10.1007/s00405-020-05965-1
- 23. Zhang HJ, Su YY, Xu SL, et al. (2020) Asymptomatic and symptomatic SARS-CoV-2 infections in close contacts of

COVID-19 patients: a seroepidemiological study. *Clin Infect Dis.* 16:ciaa771. doi: 10.1093/cid/ciaa771

- Zhao J, Yang Y, Huang H, et al. (2020) Relationship between the ABO Blood Group and the COVID-19 Susceptibility. *Clin Infect Dis.* 4:ciaa1150. doi: 10.1093/cid/ciaa1150
- 25. Cheng Y, Cheng G, Chui CH, et al. (2005) ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA. 23;293(12):1450-1. doi: 10.1001/jama.293.12.1450-c.
- Zietz M, Zucker J, Tatonetti NP. (2020) Testing the association between blood type and COVID-19 infection, intubation and death. *medRxiv*. 11:2020.04.08.20058073. doi: 10.1101/2020.04.08.20058073
- Cevik M, Tate M, Loyd O, et al. (2021) SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe*. 2(1): E13-E22. Doi.org/10.1016/S2666-5247(20)30172-5